Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vera Therapeutics
Pharma
Vera’s strong ph. 3 Trutakna data intensify IgAN rivalry
Trutakna reduced the risk of composite kidney disease progression by 76% versus placebo over two years.
Angus Liu
Sep 16, 2026 2:50pm
In a first, Otsuka’s Voyxact stabilizes IgAN kidney loss in ph.3
Aug 3, 2026 5:00pm
Vera’s dual-target atacicept wins FDA approval for IgAN
Jul 7, 2026 12:23pm
Top 10 most anticipated drug launches of 2026
Feb 2, 2026 3:00am
